Drugs / STP206
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01954017 | Jan 2014 → Feb 2018 | necrotizing enterocolitis | Leadiant Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00922324 | Mar → Jun 2010 | — | Leadiant Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STP206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01954017 ↗ |
| Modality | Other / unclassified | “STP206 Live Biotherapeutic” NCT00922324 ↗ |
| Route | Oral | “daily oral administration” NCT00922324 ↗ |